Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05)

被引:174
作者
Roos, DE [1 ]
Turner, SL
O'Brien, PC
Smith, JG
Spry, NA
Burmeister, BH
Hoskin, PJ
Ball, DL
机构
[1] Royal Adelaide Hosp, Adelaide, SA 5000, Australia
[2] Westmead Hosp, Westmead, NSW, Australia
[3] Newcastle Mater Misericordiae Hosp, Newcastle, NSW, Australia
[4] Peter MacCallum Canc Inst, Ctr Stat, Melbourne, Australia
[5] Sir Charles Gairdner Hosp, Nedlands, WA 6009, Australia
[6] Princess Alexandra Hosp, Woolloongabba, Qld 4102, Australia
[7] Mt Vernon Hosp, Marie Curie Res Wing, Northwood HA6 2RN, Middx, England
[8] Peter MacCallum Canc Ctr, Melbourne, Australia
关键词
bone metastases; neuropathic pain; radiotherapy; randomized trial;
D O I
10.1016/j.radonc.2004.09.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Despite numerous randomized trials investigating radiotherapy (RT) fractionation schedules for painful bone metastases, there are very few data on RT for bone metastases causing pain with a neuropathic component. The Trans-Tasman Radiation Oncology Group undertook a randomized trial comparing the efficacy of a single 8 Gy (8/1) with 20 Gy in 5 fractions (20/5) for this type of pain. Materials and methods: Eligible patients had radiological evidence of bone metastases from a known malignancy with no change in systemic therapy within 6 weeks before or anticipated within 4 weeks after RT, no other metastases along the distribution of the neuropathic pain and no clinical or radiological evidence of cord/cauda equina compression. All patients gave written informed consent. Primary endpoints were pain response within 2 months of commencement of RT and time to treatment failure (TTF). The hypothesis was that 8/1 is at least as effective as 20/5 and the planned sample size was 270 patients. Results: Between February 1996 and December 2002, 272 patients were randomized (8/1:20/5 = 137:135) from 15 centres (Australia 11, New Zealand 3, UK 1). The commonest primary cancers were lung (31%), prostate (29%) and breast (8%); index sites were spine (89%), rib (9%), other (2%); 72% of patients were males and the median age was 67 (range 2989). The median overall survival (95% CI) for all randomized patients was 4.8 mo (4.2-5.7 mo). The intention-to-treat overall response rates (95% Cl) for 8/1 vs 20/5 were 53% (45-62%) vs 61% (53-70%), P = 0.18. Corresponding figures for complete response were 26% (18-34%) vs 27% (19-35%), P = 0.89. The estimated median TTFs (95% CI) were 2.4 mo (2.0-3.3 mo) vs 3.7 mo (3.1-5.9 mo) respectively. The hazard ratio (95% Cl) for the comparison of TTF curves was 1.35 (0.99-1.85), log-rank P = 0.056. There were no statistically significant differences in the rates of re-treatment, cord compression or pathological fracture by arm. Conclusions: 8/1 was not shown to be as effective as 20/5, nor was it statistically significantly worse. Outcomes were generally poorer for 8/1, although the quantitative differences were relatively small. (c) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:54 / 63
页数:10
相关论文
共 21 条
[1]  
ARMITAGE P, 1994, STAT METHODS MED RES, P201
[2]  
Ashton A, 1999, RADIOTHER ONCOL, V52, P111
[3]   Palliative radiation for vertebral metastases: The effect of variation in prescription parameters on the dose received at depth [J].
Barton, R ;
Robinson, G ;
Gutierrez, E ;
Kirkbride, P ;
McLean, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (04) :1083-1091
[4]  
Bonica JJ, 1990, MANAGEMENT PAIN, P133
[5]   International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases [J].
Chow, E ;
Wu, JSY ;
Hoskin, P ;
Coia, LR ;
Bentzen, SM ;
Blitzer, PH .
RADIOTHERAPY AND ONCOLOGY, 2002, 64 (03) :275-280
[6]  
Crellin A M, 1989, Clin Oncol (R Coll Radiol), V1, P63, DOI 10.1016/S0936-6555(89)80036-6
[7]  
*CYT SOFTW CORP, 2001, STATX 5 0 3
[8]  
*CYT SOFTW CORP, 1999, LOGX 4 0 2
[9]  
*DAT AN PROD DIV M, 1999, S PLUS 2000 4 0 3
[10]  
Jones B, 1996, BRIT MED J, V313, P550